Open report — full analysis, no account required.
Sign up to generate reports and read filings that aren't on the open list.
Get notified when LAB files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsStandard BioTools receives $30M Illumina buyout, sells mass cytometry for $5M note
Filed July 28, 2026 · Period ending July 24, 2026 · ~1 min read
Key Changes
-
high
Item 1.01 verify on EDGAR →
-
high
Agreed to sell mass cytometry business to Multiplex Bio for $5M five-year note at 6% interest (no upfront cash) plus potential $5M earnout, with closing contingent on shareholder approval and completion of the Treeline merger.
Item 1.01 verify on EDGAR → -
medium
May be required to provide up to $10M working capital loan to Multiplex Bio at closing if the buyer cannot secure third-party financing, creating potential additional cash outflow and credit risk.
Item 1.01 verify on EDGAR → -
medium
FTC granted early termination of HSR waiting period for Treeline merger on July 21, 2026, clearing one regulatory hurdle; transaction expected to close by end of 2026 subject to stockholder approval.
Exhibit 99.1 view on EDGAR → -
medium
Disclosed risk of failing to maintain Nasdaq listing and potential disposition of Microfluidics business, indicating broader portfolio restructuring under consideration.
Item 7.01 verify on EDGAR →
Summary
Standard BioTools disclosed two significant transactions that accelerate its portfolio rationalization. The company received approximately $30 million in cash from Illumina to terminate earnout and royalty rights stemming from the January 2026 sale of its proteomics business, converting uncertain future revenue streams into immediate liquidity.
This cash will increase Standard BioTools' pro forma net cash position in the pending Treeline Biosciences merger, affecting the exchange ratio calculation. Simultaneously, Standard BioTools agreed to sell its mass cytometry business (CyTOF and Hyperion product lines) to Multiplex Bio for $5 million, structured entirely as a five-year promissory note at 6% interest with no upfront cash.
The company may receive an additional $5 million earnout if Multiplex Bio completes a qualifying sale above a specified threshold within ten years. Notably, Standard BioTools may be required to provide up to $10 million in working capital financing to the buyer if Multiplex Bio cannot secure third-party financing before closing, creating potential additional cash outflow and credit exposure. Both the mass cytometry sale and the Treeline merger require shareholder approval, with the mass cytometry closing also contingent on completion of the Treeline transaction. The FTC granted early termination of the HSR waiting period for the Treeline merger on July 21, 2026. The filing also disclosed risks around maintaining the Nasdaq listing and a potential disposition of the Microfluidics business, suggesting broader restructuring efforts are underway. Investors should monitor the shareholder votes and the interdependent closing conditions between these transactions.
Section-by-Section Diff
Event · Item 1.01 — Entry into a Material Definitive Agreement
Item 1.01 — Entry into a Material Definitive Agreement filed; see Key Changes for terms.
Added in current filing · verify on EDGAR →
On July 24, 2026, Standard BioTools Inc., a Delaware corporation (the “Company”), entered into a Termination, Waiver and Release Agreement (the “Termination Agreement”) with Illumina, Inc., a Delaware corporation (“Illumina”). Pursuant to the terms of the Termination Agreement, the Company has received a payment of approximately $30 million in cash from Illumina in exchange for the waiver and release of certain earnout and royalty payment obligations and the termination of certain other agreements described below.
Standard BioTools received approximately $30 million in cash from Illumina to waive its rights to a 2026 earnout payment based on SomaScan assay revenues and to terminate royalty agreements related to SOMAmer-based products. This converts uncertain future revenue streams into immediate cash, simplifying the company's financial structure following the January 2026 sale of its proteomics business to Illumina.
Added in current filing · verify on EDGAR →
On July 28, 2026, the Company entered into a Share and Asset Purchase Agreement (the “Purchase Agreement”) with Multiplex Bio Inc., a Delaware corporation (“Multiplex Bio”). Pursuant to the Purchase Agreement, on the terms and subject to the conditions set forth therein, Multiplex Bio will acquire the mass cytometry business (the “Business”) of the Company (collectively, the “Transaction”).
Under the Purchase Agreement, the aggregate purchase price for the Transaction is $5 million, on a cash-free and debt-free basis and subject to customary adjustments contemplated by the Purchase Agreement (as so adjusted, the “Closing Payment”). The Closing Payment is payable entirely through the issuance to the Company by Multiplex Bio, at the consummation of the Transaction (the “Closing”), of a promissory note in a principal amount equal to the Closing Payment, bearing interest at a rate of 6% per annum and maturing on the fifth anniversary of the Closing. The Company will not receive cash consideration at the Closing.
Standard BioTools agreed to sell its mass cytometry business to Multiplex Bio for $5 million, structured as a five-year promissory note at 6% interest with no upfront cash. The company may receive an additional $5 million earnout if Multiplex Bio completes a qualifying sale transaction above a specified threshold within ten years. This represents a continued portfolio rationalization, though the deferred payment structure and potential working capital loan requirement (up to $10 million) indicate execution risk.
Added in current filing · verify on EDGAR →
The Purchase Agreement contains customary representations, warranties and covenants by the parties, and the consummation of the Transaction is subject to customary closing conditions. Receipt of approval of the Company’s stockholders for the Transaction, as well as consummation of the Company’s pending merger with Treeline Biosciences, Inc., are also conditions to the Closing.
The mass cytometry sale requires both shareholder approval and completion of Standard BioTools' pending merger with Treeline Biosciences. This creates execution interdependency between two major transactions, with the sale potentially delayed or at risk if either the shareholder vote or the Treeline merger encounters obstacles.
Show 1 minor / wording change
Added in current filing · verify on EDGAR →
Upon termination of the Purchase Agreement under specified circumstances, the Company will be required to make a payment to Multiplex Bio equal to $1 million in cash (the “Termination Fee”). The Company will be required to reimburse Multiplex Bio’s reasonable out-of-pocket fees in connection with the Transaction in an amount up to $125,000 if the Transaction is not consummated prior to December 31, 2026, and up to an additional $125,000 if the Transaction is not consummated prior to March 31, 2027, with the amount of any such reimbursement to be credited against any payment of the Termination Fee.
Standard BioTools faces a $1 million termination fee under specified circumstances, plus potential expense reimbursements up to $250,000 if closing delays extend beyond year-end 2026 and Q1 2027. These provisions create downside risk if the transaction fails to close, though the expense reimbursements would offset any termination fee payment.
Event · Item 7.01 — Regulation FD Disclosure
Standard BioTools announced transactions involving its Mass Cytometry business disposition and a Treeline transaction, both requiring stockholder approval.
Added in current filing · verify on EDGAR →
the disposition of the Mass Cytometry business; the expected timing of the disposition of the Mass Cytometry business
Standard BioTools disclosed plans to sell its Mass Cytometry business. The transaction requires stockholder approval and is subject to various closing conditions. The filing does not disclose financial terms, the buyer's identity, or specific timing.
Added in current filing · verify on EDGAR →
the Treeline transaction; the expected timing of the closing of the Treeline transaction; the potential benefits of the Treeline transaction; the prospective performance and outlook of the combined company’s business, performance and opportunities
Standard BioTools announced a transaction with Treeline that will create a combined company. The company filed a registration statement on Form S-4 on July 20, 2026 that included a preliminary proxy statement and prospectus. The transaction requires stockholder approval and is subject to closing conditions. The filing references anticipated benefits and the combined company's outlook but does not disclose specific financial terms.
Added in current filing · verify on EDGAR →
the ability to obtain the requisite approval for the sale of the Mass Cytometry business from stockholders of Standard BioTools ... the ability to obtain the requisite approval for the sale of the Treeline transaction from stockholders of Standard BioTools
Both the Mass Cytometry business sale and the Treeline transaction require stockholder approval. Standard BioTools will file proxy materials with the SEC for stockholders to vote on these transactions. The company has already filed a registration statement on Form S-4 on July 20, 2026 for the Treeline transaction and will file a preliminary proxy statement for the Mass Cytometry disposition.
Added in current filing · verify on EDGAR →
the risk that the potential disposition of Standard BioTools’ Microfluidics business may not be completed on favorable terms or at all
The filing discloses that Standard BioTools is considering a potential disposition of its Microfluidics business, though this transaction may not be completed. This suggests the company is evaluating a broader portfolio restructuring beyond the Mass Cytometry sale and Treeline transaction.
Added in current filing · verify on EDGAR →
the risk that Standard BioTools could fail to maintain the listing of its common stock on Nasdaq
The company disclosed a risk that it could fail to maintain its Nasdaq listing. This suggests potential compliance concerns related to listing standards, which could be affected by the proposed transactions or the company's current financial condition.
Event · Exhibit 99.1
Standard BioTools sells Mass Cytometry business for up to $10M, receives $30M Illumina earnout/royalty buyout, and obtains FTC clearance for Treeline merger.
Added in current filing · view on EDGAR →
The transaction is valued at up to $10 million, comprising a seller’s note issued by Multiplex Bio to Standard BioTools and a potential milestone payment. Standard BioTools has agreed to provide Multiplex Bio with a working capital loan of up to $10 million at the closing of the transaction.
Standard BioTools is selling its Mass Cytometry business (CyTOF and Hyperion product lines) to Multiplex Bio, a new entity led by advanced imaging industry veterans. The deal is valued at up to $10 million in seller's note and milestone payments, with Standard BioTools providing a $10 million working capital loan to the buyer. The transaction is expected to close by end of 2026, concurrent with the Treeline merger, subject to stockholder approval.
Added in current filing · view on EDGAR →
Standard BioTools received approximately $30 million as a buyout of the 2026 earnout and all accrued and unpaid royalty payments related to Illumina, Inc.’s previously completed acquisition of Standard BioTools’ SomaLogic business. This payment will now be included in Standard BioTools’ pro forma net cash position at closing of the Treeline transaction, which will be used in determining the value of Standard BioTools in the exchange ratio in the Treeline transaction, in each case subject to the terms of the merger agreement with Treeline.
Standard BioTools received approximately $30 million from Illumina as a negotiated buyout of the 2026 earnout and all future royalty payments related to Illumina's prior acquisition of Standard BioTools' SomaLogic business. This cash will be included in Standard BioTools' pro forma net cash position at closing of the Treeline merger and will affect the exchange ratio calculation for that transaction.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Jul 29, 2026 · How we verify